The impact of monoclonal antibodies in preventing antimicrobial resistance (AMR) DOI Open Access
Raja Chakraverty,

Jyotirmoy Bondyopadhyay,

Tatini Debnath

et al.

Indian Journal of Pharmacy and Pharmacology, Journal Year: 2024, Volume and Issue: 11(1), P. 23 - 28

Published: May 7, 2024

Monoclonal antibodies (mAbs) have transformed modern medicine through precision targeting and therapeutic efficacy. This summary summarises the development, applications, comparative characteristics of mAbs in context antiviral medicines antibiotic treatment durations. are designed to target specific antigens with great affinity specificity, making them important for diagnostics treatments. Anti-virulence mAbs, a type mAb, pathogen virulence factors rather than pathogens themselves, providing promising technique combating infectious diseases while limiting resistance development. When comparing duration medication versus mAb treatment, frequently provide shorter more tailored regimen. can lead better patient outcomes, less resistance, lower risk side effects associated long-term usage. Antigen selection, hybridoma creation, antibody synthesis, purification, characterization all steps development process, advances like recombinant DNA technology improving efficiency scalability.

Language: Английский

Development of Microneedles for Antimicrobial Drug Delivery: A Comprehensive Review on Applications in Wound Infection Management DOI Creative Commons
Hanif Haidari, Richard Bright, Yunlong Yu

et al.

Small Science, Journal Year: 2024, Volume and Issue: unknown

Published: July 21, 2024

Microneedles (MNs) have emerged as a promising transdermal antimicrobial delivery system, providing precise and localized drug while complemented with noninvasiveness patient compliance. Currently, the topical application of antimicrobials restricts drugs to critical areas wound bed, largely due barriers posed by necrotic tissue, scab formation, bacterial biofilms, which severely diminish bioavailability therapeutics. MNs enabled efficient targeted overcome many chronic challenges. Over past decade, significant progress has been made develop unique properties tailored for vaccines, anticancer, antimicrobials. As ongoing research continues refine MN design, material properties, formulations, potential revolutionizing efficacy, experience, therapeutic outcomes remains at forefront scientific research. In this review, insights are provided into latest progress, current developments, diverse applications delivery. Herein, translational is highlighted perspective on challenges associated clinical translation provided. Furthermore, review aids in identifying gaps empowering contributing future implementation cutting‐edge systems effectively tackle resistance.

Language: Английский

Citations

7

3D bioprinted microneedles: merging drug delivery and scaffold science for tissue-specific applications DOI Creative Commons
Mershen Govender, Sunaina Indermun, Yahya E. Choonara

et al.

Expert Opinion on Drug Delivery, Journal Year: 2024, Volume and Issue: 21(11), P. 1559 - 1572

Published: May 9, 2024

Three-Dimensional (3D) microneedles have recently gained significant attention due to their versatility, biocompatibility, enhanced permeation, and predictable behavior. The incorporation of biological agents into these 3D constructs has advanced the traditional microneedle an effective platform for wide-ranging applications.

Language: Английский

Citations

6

Advances in the development of medical dressings for the treatment of diabetic foot wounds DOI
Ming Cai, Zhao Liu,

Xun Sun

et al.

Chemical Engineering Journal, Journal Year: 2024, Volume and Issue: 498, P. 155575 - 155575

Published: Sept. 7, 2024

Language: Английский

Citations

5

Emerging strategies for treating medical device and wound‐associated biofilm infections DOI Creative Commons
Chenlong Wang, Yajuan Su, S. M. Shatil Shahriar

et al.

Microbial Biotechnology, Journal Year: 2024, Volume and Issue: 17(10)

Published: Oct. 1, 2024

Bacterial infections represent a significant global threat to human health, leading considerable economic losses through increased healthcare costs and reduced productivity. One major challenge in treating these is the presence of biofilms - structured bacterial communities that form protective barriers, making traditional treatments less effective. Additionally, rise antibiotic-resistant bacteria has exacerbated treatment difficulties. To address challenges, researchers are developing exploring innovative approaches combat biofilm-related infections. This mini-review highlights recent advancements following key areas: surface anti-adhesion technologies, electricity, photo/acoustic-active materials, endogenous mimicking agents, drug delivery systems. These strategies aim prevent biofilm formation, disrupt existing biofilms, enhance efficacy antimicrobial treatments. Currently, show great potential for applications medical fields such as device wound associated By summarizing developments, this provides comprehensive resource seeking advance management biofilm-associated

Language: Английский

Citations

5

Origami of KR-12 Designed Antimicrobial Peptides and Their Potential Applications DOI Creative Commons

Jayaram Lakshmaiah Narayana,

Abraham Fikru Mechesso, Imran Rather

et al.

Antibiotics, Journal Year: 2024, Volume and Issue: 13(9), P. 816 - 816

Published: Aug. 28, 2024

This review describes the discovery, structure, activity, engineered constructs, and applications of KR-12, smallest antibacterial peptide human cathelicidin LL-37, production which can be induced under sunlight or by vitamin D. It is a moonlighting that shows both antimicrobial immune-regulatory effects. Compared to KR-12 extremely appealing due its small size, lack toxicity, narrow-spectrum activity. Consequently, various peptides have been tune activity stability via amino acid substitution, end capping, hybridization, conjugation, sidechain stapling, backbone macrocyclization. We also mention recently discovered KR-8 RIK-10 are shorter than KR-12. Nano-formulation provides an avenue targeted delivery, controlled release, increased bioavailability. In addition, has covalently immobilized on biomaterials/medical implants prevent biofilm formation. These constructs with enhanced potency demonstrated eradicate drug-resistant pathogens, disrupt preformed biofilms, neutralize endotoxins, regulate host immune responses. Also highlighted safety efficacy these in topical systemic animal models. Finaly, we summarize achievements discuss future developments as cosmetic preservatives, novel antibiotics, anti-inflammatory peptides, microbiota-restoring agents.

Language: Английский

Citations

4

Nanomaterial-Enhanced Microneedles: Emerging Therapies for Diabetes and Obesity DOI Creative Commons
Mehrnaz Abbasi,

Divine Afunu Boka,

Hannah DeLoit

et al.

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(10), P. 1344 - 1344

Published: Oct. 21, 2024

Drug delivery systems (DDS) have improved therapeutic agent administration by enhancing efficacy and patient compliance while minimizing side effects. They enable targeted delivery, controlled release, bioavailability. Transdermal drug (TDDS) offer non-invasive medication evolved to include methods such as chemical enhancers, iontophoresis, microneedles (MN), nanocarriers. MN technology provides innovative solutions for chronic metabolic diseases like diabetes obesity using various types. For management, MNs continuous glucose monitoring, diabetic wound healing, painless insulin delivery. treatment, provide sustained transdermal of anti-obesity drugs or nanoparticles (NPs). Hybrid integrating wearable sensors smart materials enhance treatment effectiveness management. Nanotechnology has advanced nano-scaled liposomes polymeric NPs with MNs. In glucose-responsive facilitate At the same time, lipid nanocarriers in dissolving extended release stability absorption disorder therapies. DDS are advancing toward personalized treatments enhanced nanomaterials. These approaches can outcomes through precise real-time monitoring. However, widespread implementation faces challenges ensuring biocompatibility, improving technologies, scaling production, obtaining regulatory approval. This review will present recent advances developing applying nanomaterial-enhanced management also discussing challenges, limitations, future perspectives these DDS.

Language: Английский

Citations

4

Versatile nanomaterials used in combatting biofilm infections DOI
Chenlong Wang, S. M. Shatil Shahriar, Yajuan Su

et al.

Nanomedicine, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 18

Published: Jan. 31, 2025

Microbial infections are a pressing global health issue, exacerbated by the rise of antibiotic-resistant bacteria due to widespread antibiotic overuse. This resistance diminishes effectiveness current treatments, intensifying need for new antimicrobial agents and innovative drug delivery strategies. Nanotechnology presents promising solutions, leveraging unique properties nanomaterials such as tunable optical electronic characteristics, nanoscale size, high surface-to-volume ratios. These features enhance their versatile systems. minireview classifies into four categories based on mechanisms action: thermal generation, reactive oxygen species gas nanocarrier systems liposomes, polymersomes, metal-organic frameworks. Uniquely, this review integrates comparative analysis these mechanisms, highlighting relative advantages, limitations, applications across diverse microbial targets. Additionally, it identifies emerging trends in field, providing forward-looking perspective how recent advancements nanotechnology can be leveraged address unmet clinical needs. Finally, article discusses future directions opportunities nanotechnology.

Language: Английский

Citations

0

A New Insight into Phage Combination Therapeutic Approaches Against Drug-Resistant Mixed Bacterial Infections DOI Open Access

Mohammadreza Rahimian,

Davoud Jafari-Gharabaghlou, Elham Mohammadi

et al.

PHAGE, Journal Year: 2024, Volume and Issue: 5(4), P. 203 - 222

Published: Oct. 17, 2024

Rising antibiotic resistance among bacterial pathogens has become a substantial health issue for human civilization. The emergence of these in high-risk diseases such as cystic fibrosis (CF) led to financial and nonfinancial losses, necessitating alternative therapies. This study presents an overview approaches, including phage therapy, antimicrobial peptides (AMPs), nanotechnology, monoclonal antibodies (mAbs), microbial therapies (probiotic therapy), clustered regularly interspaced short palindromic repeats technology (CRISPR), aptamers focusing on their mechanisms action exploring the impact combining derivatives with mentioned approaches. Although approaches combinations phages show promise, phage-antibiotic combination been subject most studies, It proven be highly effective combating antibiotic-resistant infections. Other also appear promising, but further studies are needed determine effectiveness. emphasizes need more thorough research into different treatments beyond well-established strategy.

Language: Английский

Citations

2

The impact of monoclonal antibodies in preventing antimicrobial resistance (AMR) DOI Open Access
Raja Chakraverty,

Jyotirmoy Bondyopadhyay,

Tatini Debnath

et al.

Indian Journal of Pharmacy and Pharmacology, Journal Year: 2024, Volume and Issue: 11(1), P. 23 - 28

Published: May 7, 2024

Monoclonal antibodies (mAbs) have transformed modern medicine through precision targeting and therapeutic efficacy. This summary summarises the development, applications, comparative characteristics of mAbs in context antiviral medicines antibiotic treatment durations. are designed to target specific antigens with great affinity specificity, making them important for diagnostics treatments. Anti-virulence mAbs, a type mAb, pathogen virulence factors rather than pathogens themselves, providing promising technique combating infectious diseases while limiting resistance development. When comparing duration medication versus mAb treatment, frequently provide shorter more tailored regimen. can lead better patient outcomes, less resistance, lower risk side effects associated long-term usage. Antigen selection, hybridoma creation, antibody synthesis, purification, characterization all steps development process, advances like recombinant DNA technology improving efficiency scalability.

Language: Английский

Citations

0